05/21/2025
GlobaLASEReach is pleased to announce the addition of Dr. Tanaz Ferzandi, MD, to its Advisory Board
Overview
Tanaz Ferzandi, MD, MBA, MA joined Keck Medicine of USC as the Director of Urogynecology and Reconstructive Pelvic Surgery in December 2019. She is the service line Chief of Obstetrics and Gynecology at Keck Hospital of USC. Dr. Ferzandi is also an Associate Professor of Obstetrics and Gynecology at the Keck School of Medicine of USC and Associate Fellowship Director for Urogynecology and Reconstructive Pelvic Surgery. In 2023, she was elected to serve as the secretary and treasurer of the Keck Hospital Medical Executive Staff, in line to become chief of staff in the upcoming years. Dr. Ferzandi completed her medical degree and her master’s degree in cell biology at the University of Kansas Medical Center. She then completed her residency in Obstetrics and Gynecology followed by a three-year fellowship in Urogynecology and Reconstructive Pelvic Surgery at Harvard University. Given her interest in health care policy and business, Dr. Ferzandi obtained her Master’s degree in Business Administration from the Heller School for Social Policy and Management at Brandeis University.
​
Given her extensive practice and leadership background in OB/GYN, including specific expertise in the urogynecologic space, Dr. Ferzandi's contributions will be critical given that our lead indication is currently the intravaginal PBM treatment of women suffering from chronic pain and a variety of OB/GYN syndromes. She will assist the company with its strategic development, R&D efforts, positioning the company's products within the medical community (including potential PBM opportunities within female chronic pain and OB/GYN-related conditions), positioning our technology with influential medical societies, and access to her network within the medical community.
03/24/2025
GlobaLASEReach Enters Agreement With Vitanova Medical on Oncology Treatment Activation
Overview
GlobaLASEReach Inc. and Vitanova Biomedical Inc. have signed a Letter of Intent to enter into a definitive collaboration agreement. The companies are interested in collaborating with the intent to commercialize laser-activated cancer treatments based upon GlobaLASEReach’s laser technology, expertise, and IP together with Vitanova's cancer drug technology, expertise, and IP. GlobaLASEReach Inc. will focus on the development of the Rezalox Therapy System to support the performance of Vitanova’s Light-Activated Intracellular Acidosis (LAIA) therapy for the treatment of various cancers. Vitanova Biomedical Inc. will focus on the development of nanoparticle technology which may be targeted to specific cancer cell types, leading to cancer cell death only when activated by laser light.
​
03/10/2025
Advancing Photobiomodulation Therapy: The Impact of Our Patented Cooled Handpiece on Surface Temperature
Introduction
One of the key challenges in photobiomodulation therapy is managing surface temperature to ensure patient comfort and safety without compromising treatment efficacy. At GlobaLASEReach, an experiment was conducted to compare temperature differences between a non-cooled open airbridge handpiece and our newly patented cooled handpiece. The non-cooled open airbridge handpiece is commonly used by our competitors, making our advanced cooling technology a major competitive advantage. The results highlight a significant advancement in
photobiomodulation treatment technology.
The Experiment Setup
To create a realistic test environment, a controlled workspace was created with a consistent temperature. The laser was configured at dual wavelengths of 810 nm and 980 nm, operating at 10 and 20 watts. We used a simulated skin surface with a starting temperature of 34 degree C to conduct the study allowing us to affect the heat experience a patient would feel during treatment. Each test cycle involved applying the laser for 30, 60, 90, and 120 seconds, measuring the surface temperature at every interval. This process was first conducted using a non-cooled open airbridge handpiece, then repeated with our patented cooled handpiece, which utilizes a chilled CO2 gas system flowing through the lens space to actively manage heat dissipation.
The Results: A Game-Changer in Photobiomodulation Therapy
The temperature difference between the two handpieces was remarkable. When using the cooled handpiece, a temperature reduction ranging from 4.5 to over 45.0 degrees centigrade was observed, compared to the non-cooled version. This decrease in surface temperature may have major implications for patient comfort, safety, and treatment effectiveness, reinforcing the importance of active cooling in high-powered laser applications.
​
Why This Matters
By significantly lowering the surface temperature during treatment, the cooled handpiece enhances treatment tolerability, reduces the risk of thermal discomfort, allows increased energy to affected tissue, and opens the door for more effective energy delivery, without compromising patient experience. Additionally, the ability to maintain lower surface temperatures enables longer treatment durations, which is critical for maximizing therapeutic effects. Extended exposure times allow for greater energy absorption at targeted depths, improving overall treatment outcomes. This technology is another step forward in making photobiomodulation therapy safer, more precise, and ultimately more effective for both
practitioners and patients.
